Old and new antirheumatic drugs for the treatment of COVID-19

Benucci, Maurizio; Damiani, Arianna; Infantino, María; Manfredi, Mariangela; Quartuccio, Luca

doi:10.1016/j.jbspin.2020.03.013

Cited by 28 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2020b ). Inhibition of TNF-α by the monoclonal antibodies such as Infliximab and Adalimumab, can inhibit the non-canonical activation of NF-κB pathway which has the potential to be used to alleviate symptoms in severely ill COVID patients (Feldmann et al 2020 ; Benicco et al 2020 ). It was noted that out of 536 COVID-19 patients who were on regular anti-TNF-α as treatment for their existing inflammatory bowel disease (IBD), 448 (84%) patients were treated as outpatient and only 84 (15%) were hospitalised.…”

Section: Introductionmentioning

confidence: 99%

The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic has affected health care systems worldwide. Severe presentations of COVID-19 such as severe pneumonia and acute respiratory distress syndrome (ARDS) have been associated with the post-viral activation and release of cytokine/chemokines which leads to a “cytokine storm” causing inflammatory response and destruction, mainly affecting the lungs. COVID-19 activation of transcription factor, NF-kappa B (NF-κB) in various cells such as macrophages of lung, liver, kidney, central nervous system, gastrointestinal system and cardiovascular system leads to production of IL-1, IL-2, IL-6, IL-12, TNF-α, LT-α, LT-β, GM-CSF, and various chemokines. The sensitised NF-κB in elderly and in patients with metabolic syndrome makes this set of population susceptible to COVID-19 and their worse complications, including higher mortality. Immunomodulation at the level of NF-κB activation and inhibitors of NF-κB (IκB) degradation along with TNF-α inhibition will potentially result in a reduction in the cytokine storm and alleviate the severity of COVID-19. Inhibition of NF-κB pathway has a potential therapeutic role in alleviating the severe form of COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…On one hand, anti-inflammatory drugs and DMARD are necessary for keeping inflammatory chronic diseases or painful and crippling degenerative diseases under control and, on the other hand, are of concern for increasing the risk of COVID-19 among patients with rheumatic diseases. Paradoxically, emerging scientific literature reports a potential use of certain DMARDs in the prevention or the treatment of COVID-19 [2,3]. Currently, there is little evidence to support that patients under chronic immunosuppressive therapy are at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [4].…”

Section: Introductionmentioning

confidence: 99%

Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020

Richez

Flipo

Bérenbaum³

et al. 2020

Joint Bone Spine

View full text Add to dashboard Cite

“…Several reports suggested that SARS-CoV-2 infection may be followed by an outbreak of autoimmune and autoinflammatory diseases ( 1 ). Next, an excessive inflammation observed in SARS-CoV-2 is mediated through cytokines that are drug targets in some SARD, and thus similar drugs were suggested to control excessive inflammatory reactions, e.g., the blockade of interleukin-6 (IL-6) signaling ( 2 ). Finally, a common point between infections and autoimmune diseases is the enhanced susceptibility of patients with SARD to infection as well as potentially altered course of infection due to immunomodulatory treatment ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases

et al. 2021

View full text Add to dashboard Cite

Autoimmune diseases and infections are often closely intertwined. Patients with autoimmune diseases are more susceptible to infections due to either active autoimmune disease or the medications used to treat them. Based on infections as environmental triggers of autoimmunity, an autoimmune response would also be expected in COVID-19. Although some studies have shown the occurance of autoantibodies and the possible development of autoimmune diseases after SARS-CoV-2 infection, current data suggest that the levels of autoantibodies following SARS-CoV-2 infection is comparable to that of some other known infections and that the autoantibodies might only be transient. The risk of SARS-CoV-2 infection in patients with a systemic autoimmune rheumatic disease (SARD) appears slightly higher compared to the general population and the course of COVID-19 disease does not seem to be very different, however, specific therapies such as glucocorticoids and anti-TNF might modulate the risk of hospitalization/death. Cytokine release syndrome is a severe complication in COVID-19. Many drugs used for the treatment of SARD are directly or indirectly targeting cytokines involved in the cytokine release syndrome, therefore it has been suggested that they could also be effective in COVID-19, but more evidence on the use of these medications for the treatment of COVID-19 is currently being collected.

show abstract

Old and new antirheumatic drugs for the treatment of COVID-19

Cited by 28 publications

References 25 publications

The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients

The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients

Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020

COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases

Contact Info

Product

Resources

About